97.78

0.64% -0.63

Jazz Pharmaceuticals Plc (JAZZ)

Overview News Price History Option Chain Financials Discussions Forecast

Jazz Pharmaceuticals Plc stock is traded at $97.78, with a volume of 1.22M. It is down -0.64% in the last 24 hours and down -11.21% over the past month. Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Previous Close:

$98.41

Open:

$98.61

24h Volume:

1.22M

Relative Volume:

0.98

Market Cap:

$7.40B

Revenue:

$3.99B

Net Income/Loss:

$463.16M

P/E Ratio:

13.77

EPS:

7.1

Net Cash Flow:

$1.10B

1W Performance:

-18.55%

1M Performance:

-11.21%

6M Performance:

-20.90%

1Y Performance:

-13.56%

1-Day Range:

$97.56

$99.98

1-Week Range:

$97.50

$120.57

52-Week Range:

$95.49

$148.06

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name

Jazz Pharmaceuticals Plc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

353-1-634-7800

Address

FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN

Employee

2,800

Twitter

@jazzpharma

Next Earnings Date

2024-11-06

Latest SEC Filings

JAZZ's Discussions on Twitter

Compare JAZZ with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JAZZ Jazz Pharmaceuticals Plc	97.78	7.40B	3.99B	463.16M	1.10B	7.10
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-25	Upgrade	UBS	Neutral → Buy
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-05-24	Initiated	Goldman	Buy
Jan-03-24	Initiated	Robert W. Baird	Outperform
Nov-27-23	Downgrade	UBS	Buy → Neutral
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight
Dec-09-22	Upgrade	Goldman	Neutral → Buy
Jun-14-22	Initiated	UBS	Buy
Apr-06-22	Downgrade	Goldman	Buy → Neutral
Nov-19-21	Resumed	Goldman	Buy
Oct-07-21	Resumed	Jefferies	Buy
Oct-05-21	Initiated	Citigroup	Buy
Sep-23-21	Initiated	Needham	Buy
May-19-21	Resumed	JP Morgan	Overweight
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-05-21	Reiterated	H.C. Wainwright	Buy
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight
Jan-29-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-16-20	Initiated	UBS	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Oct-09-20	Reiterated	H.C. Wainwright	Buy
Sep-14-20	Downgrade	Goldman	Neutral → Sell
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-06-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-28-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jul-23-20	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-06-20	Initiated	Jefferies	Buy
Mar-12-20	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-08-20	Initiated	Goldman	Neutral
Aug-21-19	Downgrade	Piper Jaffray	Overweight → Neutral
Jun-11-19	Initiated	Barclays	Overweight
Mar-20-19	Initiated	SunTrust	Buy
Dec-14-18	Initiated	Wolfe Research	Peer Perform
Nov-08-18	Reiterated	B. Riley FBR	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jul-11-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-23-18	Reiterated	H.C. Wainwright	Neutral
Mar-19-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight

View All

Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News

May 09, 2025

Avadel Pharma gains after appeals court ruling in Lumryz case with Jazz Pharma - MSN

May 09, 2025

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update - Yahoo Finance

May 09, 2025

Hikma $50M Deal to Settle Xyrem Antitrust Claims - USA Herald

May 09, 2025

Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st

May 09, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025

Jazz Pharma stock falls after lowered full year guidance - MSN

May 09, 2025

May 08, 2025

Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL - Law360

May 08, 2025

Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case - Reuters

May 08, 2025

JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - MSN

May 08, 2025

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com

May 08, 2025

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM) - The Globe and Mail

May 08, 2025

Decoding Jazz Pharmaceuticals PLC (JAZZ): A Strategic SWOT Insig - GuruFocus

May 08, 2025

May 07, 2025

Jazz Pharmaceuticals (JAZZ) Rating Maintained Despite Price Target Cut | JAZZ Stock News - GuruFocus

May 07, 2025

RBC Capital Maintains Outperform Rating on Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus

May 07, 2025

Jazz Pharmaceuticals (JAZZ) Target Price Lowered by Piper Sandler | JAZZ Stock News - GuruFocus

May 07, 2025

RBC Capital Adjusts Price Target for Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus

May 07, 2025

Jazz Pharmaceuticals (JAZZ): Morgan Stanley Adjusts Price Target | JAZZ Stock News - GuruFocus

May 07, 2025

Jazz Pharmaceuticals (JAZZ) Maintains Strong Momentum with 'Buy' Rating | JAZZ Stock News - GuruFocus

May 07, 2025

Jazz Pharmaceuticals (JAZZ): Among Billionaire Ray Dalio’s Bridgewater’s Stock Picks with Huge Upside Potential - Yahoo Finance

May 07, 2025

Jazz Pharmaceuticals (JAZZ) Sees Price Target Cut Amid Revenue Miss | JAZZ Stock News - GuruFocus

May 07, 2025

Morgan Stanley Cuts Price Target on Jazz Pharmaceuticals to $166 From $183, Keeps Overweight Rating - marketscreener.com

May 07, 2025

Analyst Adjusts Price Target for Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus

May 07, 2025

Jazz Pharmaceuticals plc SEC 10-Q Report - TradingView

May 07, 2025

Jazz Pharmaceuticals (JAZZ) Price Target Upgraded by BofA Analyst | JAZZ Stock News - GuruFocus

May 07, 2025

Jazz Pharmaceuticals (JAZZ) Price Target Reduced by Morgan Stanley | JAZZ Stock News - GuruFocus

May 07, 2025